The variable genomic landscape during osteosarcoma progression: insights from a longitudinal WGS analysis
Authors:
- Debora M. MeijerDMDebora M. Meijer
- Dina RuanoDRDina Ruano
- Inge H. Briaire-De BruijnIBInge H. Briaire-De Bruijn
- Pauline M. Wijers-KosterPWPauline M. Wijers-Koster
- Michiel A.J. van de SandeMichiel A.J. van de Sande
- Hans GelderblomHGHans Gelderblom
- Anne-Marie Cleton-JansenACAnne-Marie Cleton-Jansen
- Noel F.C.C. de MirandaNoel F.C.C. de Miranda
- Marieke L. KuijjerMarieke L. Kuijjer
- Judith V.M.G. BovéeJudith V.M.G. Bovée
Preprint
Abstract
Osteosarcoma is a primary bone tumor that exhibits a complex genome characterized by gross chromosomal abnormalities. Osteosarcoma patients often develop metastatic disease, resulting in limited therapeutic options and poor survival rates. To gain knowledge on the mechanisms underlying osteosarcoma heterogeneity and metastatic process, it is important to obtain a detailed profile of the genomic alterations that accompany osteosarcoma progression. We performed WGS on multiple tissue samples from six patients with osteosarcoma, including the treatment naïve biopsy of the primary tumor, resection of the primary tumor after neoadjuvant chemotherapy, local recurrence and distant metastases. SNVs and structural variants were found to accumulate over time, contributing to an increased complexity of the genome of osteosarcoma during progression. Phylogenetic trees based on SNVs and structural variants reveal distinct evolutionary patterns between patients, including linear, neutral and branched patterns. The majority of osteosarcomas showed variable copy number profiles or gained whole genome doubling in later occurrences. Additionally, chromothripsis is not confined to a single early event, as multiple other chromothripsis events may appear in later occurrences. Together, we provide a detailed analysis of the complex genome of osteosarcomas and show that five out of six osteosarcoma genomes are highly dynamic and variable during progression.Keywords
All Related Versions
- Published version: Genes, Chromosomes and Cancer, 63 (7), e23253.
This publication has 28 references indexed in Scilit:
- Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathwayThe Journal of Pathology, 2023
- TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcomaLaboratory Investigation, 2021
- The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategiesThe Journal of Pathology, 2021
- The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsNature, 2019
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet Oncology, 2019
- Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcomaNature Communications, 2017
- Tumor evolution: Linear, branching, neutral or punctuated?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017
- The Architecture and Evolution of Cancer NeochromosomesCancer Cell, 2014
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric OsteosarcomaCell Reports, 2014
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011